Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    WAveCrest Vs. Watchman
Previous Study | Return to List | Next Study

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2 (WAVECREST2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03302494
Recruitment Status : Active, not recruiting
First Posted : October 5, 2017
Last Update Posted : December 11, 2019
Sponsor:
Collaborator:
Biosense Webster, Inc.
Information provided by (Responsible Party):
Coherex Medical

Brief Summary:
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

Condition or disease Intervention/treatment Phase
Stroke Device: Coherex WaveCrest® Left Atrial Appendage Occlusion System Device: Watchman® LAA Closure Device Phase 3

Detailed Description:
The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System. Subjects will be randomized in a 1:1 ratio to the Treatment Arm (Coherex WaveCrest LAA occlusion system) or the Control Arm (Boston Scientific's Watchman LAA occlusion system). The trial is designed to demonstrate that safety and effectiveness of the WaveCrest device are non-inferior to the Watchman device.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: If the subject is suspected of having a stroke since their most recent follow-up, a Neurologist blinded to subject's randomization and implanted device must evaluate the subject or otherwise provide rationale for why an in-person neurology visit and exam are unnecessary. Neurology or blinded trial personnel should also administer mRS & NIHSS if there is suspicion of stroke A Clinical Events Committee, also blinded to subject's randomization, will adjudicate primary safety and effectiveness.
Primary Purpose: Prevention
Official Title: WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2. A Prospective, Multicenter, Randomized, Active Controlled, Clinical Trial of the Coherex WaveCrest® Left Atrial Appendage Occlusion System Compared to the Watchman® LAA Closure Device for the Reduction in Risk of Ischemic Stroke or Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation That Have an Appropriate Rationale to Seek a Non-pharmacologic Alternative to Chronic Oral Anticoagulation.
Actual Study Start Date : December 28, 2017
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: WaveCrest
WaveCrest left atrial appendage occluder
Device: Coherex WaveCrest® Left Atrial Appendage Occlusion System
Percutaneous left atrial appendage closure

Active Comparator: Watchman (control)
Watchman left atrial appendage closure device
Device: Watchman® LAA Closure Device
Percutaeous left atrial appendage closure




Primary Outcome Measures :
  1. Procedure or device related complications [ Time Frame: 45 Days ]
    Part of the composite rate of the primary safety endpoint.

  2. All Death [ Time Frame: 24 months ]
    Part of the composite rate of the primary safety endpoint.

  3. Major Bleeding [ Time Frame: 24 months ]
    Part of the composite rate of the primary safety endpoint.

  4. Ischemic stroke, systemic embolism [ Time Frame: 24 months ]
    The primary effectiveness endpoint is a composite rate of ischemic stroke or systemic embolism at 24 months


Secondary Outcome Measures :
  1. Ischemic stroke, systemic embolism [ Time Frame: 45 days ]
    The secondary endpoint is the rate of ischemic stroke or systemic embolism with the WaveCrest device in comparison to the CHADS2 and CHA2DS2-VASc imputed risk of ischemic stroke or systemic embolism in the absence of anticoagulant therapy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation
  2. At least 18 years of age
  3. Calculated CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3
  4. Indication for warfarin therapy with an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation
  5. Willing and able to comply with post-implant anticoagulation and antiplatelet regimen
  6. Willing to participate in the required follow-up visits and tests
  7. Subject has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the IRB/EC at the site

Exclusion Criteria:

  1. Atrial fibrillation (AF) due to a reversible cause (e.g. thyrotoxicosis or postoperative)
  2. Known contraindication and/or allergy to warfarin, nickel, aspirin, intravenous contrast or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel), which cannot be adequately pre-medicated or desensitized
  3. Conditions other than AF requiring long-term anticoagulation therapy
  4. Contraindications for percutaneous catheterization procedures
  5. Prior surgical LAA occlusion/exclusion or implanted with LAA occlusion device, or any prior attempt of such procedures
  6. Prior percutaneous or surgical closure of a patent foramen ovale or atrial septal defect
  7. Inability or unwillingness to take oral anticoagulation for 45 days post-procedure
  8. New York Heart Association (NYHA) Class IV heart failure
  9. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any mechanical valve implant
  10. History of symptomatic carotid, intervertebral, or intracranial artery occlusion or stenosis without revascularization with the exception of known occlusion without symptoms > 6 months
  11. Modified Rankin Scale (mRS) score ≥ 4
  12. Chronic resting heart rate ≥ 110 bpm
  13. Congenital cardiac anomalies requiring cardiac surgery or interventional repair
  14. Stroke or transient ischemic attack (confirmed by Neurologist) within 60 days prior to enrollment
  15. Myocardial infarction within 60 days prior to enrollment
  16. Sepsis or any infection requiring oral antibiotic therapy within 14 days or intravenous antibiotic therapy within 30 days prior to enrollment
  17. Surgical or interventional cardiovascular and non-cardiovascular procedure including cardioversion within 30 days prior to enrollment or AF ablation within 60 days prior to enrollment or any planned general surgery or interventional procedure within 90 days after enrollment or any planned cardiac surgery.
  18. On renal replacement therapy, serum creatinine > 3.0 mg/dl (265 μmol/L) or calculated creatinine clearance < 25 ml/minute
  19. Thrombocytopenia (<60,000 platelets/mm3), leucopenia (white blood cell count < 3,000 cells/mm³), or anemia (hemoglobin concentration < 10 grams/deciliter) based on blood work done within 30 days prior to enrollment
  20. Any medical disorder or psychiatric illness that would interfere with successful completion of the trial
  21. Currently participating in an investigational drug trial or another device trial that has not completed the primary endpoint (trials requiring extended follow-up for products that are commercially available are not considered investigational trials). Concurrent enrollment in the ACC LAAO Registry is permitted.
  22. Subject belongs to a vulnerable population (see definition in Appendix I: Acronyms and Definitions)
  23. Any condition that would reduce life expectancy to less than 2 years
  24. Women of childbearing potential who are, or plan to become pregnant during the time of the trial (method of assessment per physician discretion)

Echocardiographic Exclusion Criteria

  1. Left ventricular ejection fraction < 30%
  2. Mitral valve stenosis defined as valve area < 1.5cm2, mean gradient > 6mmHg, or any valve deformity consistent with rheumatic valvular disease
  3. Aortic valve stenosis defined as valve area ≤1.0cm2 or mean gradient >30mmHg
  4. Circumferential pericardial effusion > 10mm or symptomatic pericardial effusion
  5. Evidence of intracardiac thrombus
  6. Cardiac tumor or myxoma
  7. Atrial septal defect that warrants closure
  8. Complex atheroma in the ascending aorta or aortic arch as evidenced by mobile plaque
  9. Left Atrial Appendage size and shape are unsuitable for closure with a WaveCrest or Watchman device

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03302494


Locations
Layout table for location information
United States, Georgia
Piedmont Heart Institute
Atlanta, Georgia, United States, 30309
United States, New York
Northwell Health
Bay Shore, New York, United States, 11706
New York University- NYU Langone Cardiac
New York, New York, United States, 10016
New York University
New York, New York, United States, 10016
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Columbia University Medical Center
New York, New York, United States, 10032
United States, Texas
Baylor Scott & White All Saints Medical Center
Fort Worth, Texas, United States, 76104
Heart Hospital Baylor Plano (Baylor Research Institute)
Plano, Texas, United States, 75093
Australia
Monash Health
Melbourne, Australia
Sponsors and Collaborators
Coherex Medical
Biosense Webster, Inc.
Investigators
Layout table for investigator information
Study Chair: Vivek Reddy, MD MOUNT SINAI HOSPITAL
Study Chair: Gregg Stone, MD Columbia University

Layout table for additonal information
Responsible Party: Coherex Medical
ClinicalTrials.gov Identifier: NCT03302494    
Other Study ID Numbers: CHX_IP014
First Posted: October 5, 2017    Key Record Dates
Last Update Posted: December 11, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Coherex Medical:
Non-valvular Atrial Fibrillation
Left Atrial Appendage
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases